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Abstract
Background Acute appendicitis is the most common sur-
gical emergency and can represent a challenging diagnosis,
with a negative appendectomy rate as high as 20 %. This
review aimed to evaluate the clinical utility of individual
biomarkers in the diagnosis of appendicitis and appraise
the quality of these studies.
Methods A systematic review of the literature between
January 2000 and September 2015 using of PubMed,
OvidMedline, EMBASE and Google Scholar was con-
ducted. Studies in which the diagnostic accuracy, statistical
heterogeneity and predictive ability for severity of several
biomarkers could be elicited were included. Information
regarding costs and process times was retrieved from the
regional laboratory. European surgeons blinded to these
reviews were independently asked to rank which charac-
teristics of biomarkers were most important in acute
appendicitis to inform a cost–benefit trade-off. Sensitivity
testing and the QUADAS-2 tool were used to assess the
robustness of the analysis and study quality, respectively.
Results Sixty-two studies met the inclusion criteria and
were assessed. Traditional biomarkers (such as white cell
count) were found to have a moderate diagnostic accuracy
(0.75) but lower costs in the diagnosis of acute appen-
dicitis. Conversely, novel markers (pro-calcitonin, IL 6 and
urinary 5-HIAA) were found to have high process-related
costs including analytical times, but improved diagnostic
accuracy. QUADAS-2 analysis revealed significant poten-
tial biases in the literature.
Conclusion When assessing biomarkers, an appreciation of
the trade-offs between the costs and benefits of individual
biomarkers is needed. Further studies should seek to
investigate new biomarkers and address concerns over bias,
in order to improve the diagnosis of acute appendicitis.
Keywords Acute appendicitis  Biomarkers  Cost–benefit
trade-off
Acute appendicitis is the most common surgical emer-
gency, with an annual incidence in the USA of 9.38 per
100,000 [1]. Cases are characterized by an acute inflam-
matory process, but in approximately 16.5 % the appendix
has perforated and become gangrenous or there is overt
peritonitis, termed ‘complicated appendicitis’ [2]. Whilst in
rare special circumstances management may differ, the
mainstay of treatment for the majority of patients remains
surgery either by an open or by laparoscopic approach.
With 326,000 appendectomies performed in the USA
during 2007, at an average estimated cost of $6242 [3],
appendicitis represents a highly prevalent condition with
significant expenditure associated with its treatment.
Despite the frequency of appendicitis, accurate diagno-
sis remains difficult. The National Surgical Research Col-
laborative in the UK has estimated that the negative
appendectomy rate is as high as 20.6 % [2]. The use of
ultrasound and computerized tomography (CT) has in some
cases been shown to improve appendicitis diagnostic
accuracy and reduce the number of negative appendec-
tomies [7], with the latter shown to decrease rates to less
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than 10 % [4]. However, exposing patients to high levels of
radiation is undesirable given the lifetime risk of cancer,
along with the increase in costs associated with increased
utilization of CT, representing negatives to this approach.
Whilst this radiation dosage is avoided by using ultrasound
scanning, the technique is operator dependent, and in as
many as 55 % of cases the appendix fails to be visualized
[5].
Several studies have previously examined a variety of
biomarkers associated with appendicitis to more appropri-
ately assign risk and allocate further diagnostic investiga-
tion. These have the potential of providing noninvasive
objective criteria to aid clinicians in the diagnosis of
appendicitis and in some cases predict the severity of the
condition, with no adverse effects upon the patient. In
several studies, biomarkers have been shown to have
potentially good diagnostic accuracy and reliability, but
with variable financial and timing implications. The latter
significantly limits the clinical effectiveness of a biomarker
in the emergency setting. The ‘ideal’ diagnostic biomarker
would therefore maximize clinical utility and minimize
procedural cost including analytical time. The aim of this
study was to evaluate specific characteristics of biomarkers
that surgeons’ value and to critically assess the cost–benefit
of both traditional and novel biomarkers in the diagnosis of
acute appendicitis from published literature.
Materials and methods
Literature search strategy
A literature search of PubMed, OvidMedline, EMBASE
and Google Scholar electronic databases was conducted
from January 1, 2000, up to and including September 1,
2015, for studies regarding the use of urine or serum
biomarkers in the diagnosis of appendicitis or the predic-
tion of complicated appendicitis. Search terms used
included: appendicitis, serum, blood, urine, biomarkers,
diagnosis, diagnostics, perforation, complicated and
severity in various combinations, as well as the name of
specific biomarkers previously identified.
Research titles were then screened for suitability, and
full-text copies were retrieved. Further potentially appro-
priate papers were highlighted by assessing the reference
lists and citations of the articles being screened. All studies
that investigated the diagnostic ability of a single or mul-
tiple biomarkers that could be tested in the urine or blood
of patients were included. Exclusion criteria involved
studies with no available English translation, no full-text
edition available, and those assessing the predictive ability
of biomarkers for severity in which no diagnostic accuracy
could be calculated.
Of those studies meeting inclusion criteria, the year of
publication, population demographics, the number of
patients enrolled and the stated specificity and sensitivity of
the biomarker for diagnosis and severity were extracted.
For studies that did not explicitly state the sensitivity and
specificity of the biomarker, provided sufficient data were
available, these were independently calculated.
Literature standard
The QUADAS-2 tool was used to appraise the standard of
the literature. It was implemented, as it has been previously
described, to assess the quality and risk of bias of the
included studies [6]. The tool involves four domains:
patient selection, index test, reference standard and the
flow of subjects through the study. Prompting questions are
used to allow the reviewer to assess whether there is a risk
of bias with respect to each of the four domains. It also
allows the reviewer to gauge the applicability of the study
to the review with respect to the first three domains. In this
review, the reference standard is the histological exami-
nation of the appendix.
Biomarker survey
General surgeon members of the European Association of
Endoscopic Surgery (EAES) were asked to complete an
anonymous survey regarding their opinions on the most
desirable characteristics the ideal diagnostic biomarker of
acute appendicitis would possess (Table 1). The surgeons
were asked to rank each characteristic in the order of
importance, including diagnostic benefits (high sensitivity,
high specificity, reproducibility and predictive ability of
perforation), process-related financial costs, time for result,
ease of testing and patient acceptability. The average rank
for each of the attributes, e.g., sensitivity, was then cal-
culated, to identify which were the most desired charac-
teristics. These ranks were used to inform the weightings
for the cost–benefit trade-off, with greater importance
placed upon higher ranked attributes.
Statistical methodology
For each of the assessments of acute appendicitis and
severity of appendicitis (perforation), paired sensitivity and
specificity were calculated for diagnosis or severity, as
appropriate, from each eligible study. A bivariate model for
meta-analysis of statistical accuracy provides more accu-
rate results than fixed-effect modeling. Following the val-
idated methodology of Harbord et al. [7], bivariate meta-
analyses were therefore performed to generate pooled point
estimates and 95 % confidence intervals for the sensitivity
and specificity of the biomarker under investigation with
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histopathological confirmation of acute appendicitis, toge-
ther with hierarchical summary receiver operating charac-
teristic (ROC) curves. The software used for this analysis
was the custom-designed statistical package MIDAS [8].
Areas under the hierarchical summary ROC curves, and I2
statistics, were obtained directly from the MIDAS output.
See Zhou and Tu [9] for an in-depth description of the
statistical methods used.
Cost–benefit trade-off analysis
To evaluate the biomarkers, we applied decision analysis
methodology, employing multi-criteria decision analysis
(MCDA) [10] to assess trade-offs between cost (both time
and financial) and benefit amongst the biomarkers, in terms
of their performance characteristics (Table 2). The list of
performance characteristics was grouped into three areas,
namely monetary costs, time to results and benefits,
encompassing all the remaining characteristics that were
neither costs nor time. Through the literature review and
expert survey, we determined the mean level of perfor-
mance of the biomarkers on each of the characteristics.
Criteria on which all biomarkers had identical perfor-
mance, such as patient acceptability, were removed. The
performance level was converted to a score by assigning a
value of 0 to represent the worst performance (e.g., the
highest unit price or worst sensitivity) and a value of 100 to
represent the highest performance (e.g., lowest unit price or
highest sensitivity). We assumed linearity between per-
formance and value, such that for any intermediate level
the corresponding value was interpolated from the worst
and best performances on that criterion (valued 0 and 100,
respectively).
Criteria weightings were derived from the rankings
assigned by the European surgeons. The highest ranked
criterion was given a weighting of 100, the second highest
ranked criterion was given a weighting of 90, and so forth.
The weightings were normalized so that they totaled 1, for
each performance area. We applied a weighted average
rule to combine the value scores across criteria as in:
Table 1 Definitions of the characteristics of biomarkers the consultants were asked to rank
Definitions Outcome utilized
Sensitivity Result of pooled sensitivity for diagnosis of acute appendicitis
Specificity Results of pooled specificity for diagnosis of acute appendicitis
Predictive of perforation Area under the curve of summary ROC for diagnosis of perforated appendicitis
Cost Cost of investigation from Imperial College NHS Trust
East of testing Level of invasiveness of testing
Acceptability The impression of patient acceptability
Time for result Time from sample being taken to result being available for clinician
interpretation as described by Imperial College NHS Trust
Reproducibility I2 statistic for heterogeneity: increasing value indicates LESS consistency
Table 2 Performance of various biomarkers with respect to the surgeon rankings
Biomarker Sens. (%) Spec. (%) Ease
of test
Predictive of
perforation (%)
Cost (£) Time for
result (h)
Acceptability Reproducibility
WCC 79 55 Easy 69 2.5 1 Good 92
CRP 76 50 Easy 78 30 1 Good 81
Bilirubin 51 78 Easy 71 2 1 Good 98
Pro-calcitonin 36 88 Easy 83 17.42 12 Good 96
IL-6 73 72 Easy 84 15.5 168 Good 91
5-HIAA 72 86 Easy 0 21 240 Good 93
Surgeon rank 1 2 3 4 5 6 7 8
Acceptability considered ‘good’ as all can be done routinely. Ease of testing all considered ‘easy’ as all are noninvasive
WCC White cell count, CRP C-reactive protein, IL-6 Interleukin 6, 5-HIAA Urinary serotonin, Sens Sensitivity, Spec Specificity
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Value ¼
X
k
WkValuek;
where Vk indicates the value of an option on the kth cri-
terion and Wk is the weighting assigned to that criterion.
The overall value was therefore bounded between 0 and
100: A biomarker that had the worst performance on all the
criteria would have an overall value of 0, whereas the
biomarker that had the best performance on all the criteria
would have an overall value of 100. The more desirable the
biomarker was, the higher this value was. Two-way cost–
benefit maps highlighted the trade-offs between different
aspects of the biomarkers. Sensitivity analyses examined
the robustness of the results. Trade-off analyses were per-
formed using decision analytic software HiView (version
3.2.0.7, educational copy).
Results
Literature search
Sixty-two full-text articles met the inclusion criteria and
were appraised following the literature search (Fig. 1).
Forty-nine of these were used to assess the diagnostic
accuracy of biomarkers. Eight studies assessed urinary
markers (7 for urinary serotonin and 1 for leucine-rich gly-
coprotein). Forty-three studies investigated serum
biomarkers (23 on white cell count, 24 on C-reactive protein,
13 on bilirubin, 3 on serum amyloid A, 1 on S100 A8/9
protein, 2 on calprotectin, 7 on pro-calcitonin, 1 on D-dimer,
5 on interleukin 6, 1 on interleukin 10, 1 on leucine-rich
glycoprotein, 1 on fibrinogen, 1 on liposaccharide binding
protein and 1 on high mobility group box protein-1). Thirty-
seven studies assessed whether biomarkers were predictive
of severity (20 on white cell count, 19 on C-reactive peptide,
19 on bilirubin, 7 on pro-calcitonin, 3 on interleukin 6 and 1
on urinary serotonin) [12, 15, 20, 21, 23, 24, 26–29, 31–33,
38–41, 43, 44, 47, 48, 50, 58, 60–72]. The demographics of
these studies are shown in Appendixes 1 and 2 in ESM.
QUADAS-2 evaluation
The results of the QUADAS-2 assessment of the studies are
shown in Fig. 2. Fifty-nine percent of studies had an ‘un-
clear’ or ‘high’ risk of bias with respect to patient selection
due to constraining exclusion criteria. This limited the
applicability of fifty-eight percent of the studies with
respect to patient selection. Forty-one percent and thirty-
one percent of studies had an ‘unclear’ or ‘high’ risk of bias
with respect to the index and reference standards, respec-
tively. This was due to a lack of information regarding
blinding, thresholds and the order in which they were
assessed. Only thirteen percent of studies had an ‘unclear’
or ‘high’ risk of bias with respect to the patient flow.
Fig. 1 Schematic to show the
strategic literature search
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Biomarkers that were included in more than 2 studies
were taken forward for pooled analysis.
Pooled analysis for individual serum biomarkers
in acute appendicitis
White cell count
The pooled sensitivity of white cell count for the diagnosis
of acute appendicitis was 0.79 (95 % CI 0.78–0.81;
I2 = 92.0 %), and its pooled specificity was 0.55 (95 % CI
0.54–0.57; I2 = 88.0 %). The area under the curve for the
summary ROC was 0.75 ± 0.02. For the diagnosis of
perforated appendicitis, the pooled sensitivity was 0.70
(95 % CI 0.68–0.73; I2 = 95.5 %) and pooled specificity
was 0.49 (95 % CI 0.48–0.50; I2 = 98.5 %), giving an area
under the curve of 0.69 ± 0.05.
C-reactive protein
The pooled sensitivity of C-reactive protein for the diag-
nosis of acute appendicitis was 0.76 (95 % CI 0.75–0.78;
I2 = 81.4 %), and its pooled specificity was 0.50 (95 % CI
0.48–0.52; I2 = 94.2 %). The area under the curve for the
summary ROC was 0.80 ± 0.02. For the diagnosis of
perforated appendicitis, the pooled sensitivity was 0.76
(95 % CI 0.74–0.78; I2 = 95.2 %) and pooled specificity
was 0.52 (95 % CI 0.51–0.53; I2 98.4 %), giving an area
under the curve of 0.78 ± 0.02.
Bilirubin
The pooled sensitivity of bilirubin for the diagnosis of
acute appendicitis was 0.51 (95 % CI 0.50–0.52;
I2 = 97.7 %), and its pooled specificity was 0.78 (95 % CI
0.76–0.80; I2 = 92.0 %). The area under the curve for the
summary ROC was 0.72 ± 0.05. For the diagnosis of
perforated appendicitis, the pooled sensitivity was 0.52
(95 % C.I 0.49–0.54; I2 = 87.2 %) and pooled specificity
was 0.76 (95 % CI 0.75–0.77; I2 = 97.8 %), giving an area
under the curve of 0.71 ± 0.04.
Pro-calcitonin
The pooled sensitivity of pro-calcitonin for the diagnosis of
acute appendicitis was 0.36 (95 % CI 0.31–0.40;
I2 = 96.0 %), and its pooled specificity was 0.88 (95 % CI
0.83–0.91; I2 = 81.8 %). The area under the curve for the
summary ROC was 0.82 ± 0.10. For the diagnosis of
perforated appendicitis, the pooled sensitivity was 0.69
(95 % CI 0.62–0.76; I2 = 93 %) and pooled specificity
was 0.67 (95 % CI 0.62–0.71; I2 = 97 %), giving the area
under the curve of 0.83 ± 0.07.
IL-6
The pooled sensitivity of IL-6 for the diagnosis of acute
appendicitis was 0.73 (95 % CI 0.67–0.78; I2 = 91.1 %),
and its pooled specificity was 0.72 (95 % CI 0.63–0.79;
I2 = 62.3 %). The area under the curve for the summary
ROC was 0.74 ± 0.04. For the diagnosis of perforated
appendicitis, the pooled sensitivity was 0.79 (95 % CI
0.72–0.85; I2 = 65.1 %) and pooled specificity was 0.62
(95 % CI 0.55–0.68; I2 = 95 %), giving an area under the
curve of 0.84 ± 0.03.
Pooled analysis for 5-HIAA from urine in acute
appendicitis
The pooled sensitivity of urinary 5-HIAA for the diagnosis
of acute appendicitis was 0.72 (95 % CI 0.68–0.76;
I2 = 93.4 %), and its pooled specificity was 0.86 (95 % CI
0.80–0.92; I2 = 68 %). The area under the curve for the
summary ROC was 0.88 ± 0.07. Pooled analysis for
severity was precluded as only one study met the inclusion
criteria.
Fig. 2 A Graph displaying the percentage of studies with varying
degree of bias for each of the four QUADAS-2 domains. B Graph
displaying the percentage of studies of varying applicability with
respect to three of the four QUADAS-2 domains
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Biomarker survey
Six hundred and eighty-eight surgeon members of the EAES
responded to the survey (77 % of which were consultants,
18 % registrar level and 4 % other grades), giving a response
rate of 12.7 %. Diagnostic sensitivity was given the highest
average rank by the surgeon consensus and was thus
weighted as the most important biomarker characteristic.
The results of the other parameters are listed in Table 2.
Cost–benefit trade-off
Since all biomarkers had identical performances in terms of
‘ease of test’ and ‘acceptability,’ these two criteria were
removed from the trade-off analysis. Table 3 displays the
normalized weighted scores out of 100 for each of the six
biomarkers with respect to thecosts, time for result and benefits
(diagnostic sensitivity, specificity, prediction of perforation
and reproducibility), as well as an overall performance score.
Figure 3A displays trade-offs between the benefits, as
defined above, and the costs. White cell count and bilirubin
performed best overall with the latter scoring marginally
higher. When appraising the benefits in isolation, inter-
leukin-6 performed the best. Sensitivity analysis demon-
strated how the performance of the biomarkers would
change if the relative importance of the various charac-
teristics, as determined by the survey, was altered. If less
importance was placed upon the financial cost or the time
for result than its relative benefits (such as sensitivity), then
the surgeons’ preference would be shifted further in favor
of novel markers such as IL-6 (Fig. 3B, C).
The remaining biomarkers (C-reactive peptide, sero-
tonin and pro-calcitonin) were inferior to those previously
mentioned in a way that probabilistically dominated by the
other three tests.
Discussion
This study has highlighted the variable performance of
biomarkers in the diagnosis of appendicitis, which reduces
their potential to provide established objective criteria
when used in isolation. This analysis has shown that whilst
traditional markers including white cell count are associ-
ated with low temporal and financial cost, their overall
diagnostic accuracy is relatively poor. As such weighting
the analysis in favor of diagnostic characteristics such as
high sensitivity or specificity, as opposed to process-related
performance, would favor the use of novel biomarkers. The
low diagnostic accuracy of elevated WCC is likely due to
the presence of the underlying generalized inflammatory
process seen with acute appendicitis, but also a number of
other inflammatory conditions [12]. Conversely, novel
markers that are less commonly used clinically in the
diagnosis of appendicitis such as interleukin-6 have been
shown to have a higher diagnostic benefit, but are associ-
ated with significant costs. The results of the literature
search also highlight the expansion of work to look for
novel diagnostic biomarkers, which to date remain only
tested in isolated studies preventing meaningful analysis
for clinical application [34].
There was a ‘high’ or ‘unclear’ risk of bias in 59 % of
the studies with respect to patient selection. This was due
to insufficient information regarding selection criteria. A
number of studies assessing novel markers utilized healthy
controls, or for example, with bilirubin, excluded patients
in whom this could be caused by alternative pathology.
This, however, leads to a selection bias when assessing the
diagnostic ability of the biomarker with respect to sus-
pected appendicitis and can spuriously improve the speci-
ficity. There was also an ‘unclear’ bias with respect to the
index tests, especially with novel biomarkers, as diagnostic
thresholds were not stated. The majority of the studies
showed good applicability, but the assessment of a
restricted demographic, such as pediatric patients, limited
the studies performance with respect to this domain.
This study has highlighted the challenges associated
with using single biomarkers in the diagnosis of appen-
dicitis. Radiological investigation, especially CT, has been
shown to have far superior diagnostic ability, with a
reported sensitivity and specificity of 94 and 95 %,
respectively [73]. However, the estimated radiation dose
associated with a CT abdomen is 14mSV, equating to an
increase of 0.2 % in the cancer risk for a 30-year-old
Table 3 Normalized scores (out of 100) for the six biomarkers with respect to financial cost, time, diagnostic benefit (composite of sensitivity,
specificity, reproducibility and prediction of perforation) and overall performance
WCC CRP Bilirubin Pro-calcitonin IL-6 5-HIAA
Cost performance 98 0 100 45 52 32
Time performance 100 100 100 95 30 0
Diagnostic benefit 64.3 45 44 58 53 87
Overall performance 74.6 52.0 75.1 65.0 68.3 52.2
WCC White cell count, CRP C-reactive protein, IL-6 Interleukin 6, 5-HIAA Urinary serotonin
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patient [74]. Furthermore, CT remains a relatively expen-
sive modality that could not be practically used in all
patients in many areas of the world. Several studies have
already suggested the use of diagnostic algorithms to
ensure judicious use of radiology [73] and have demon-
strated the potential to halve the use of CT scanning
without increasing the negative appendectomy rate.
Biomarkers could therefore be incorporated into these
diagnostic algorithms in order to rationalize and more
appropriately allocate further investigations.
Previous studies on biomarkers in appendicitis have
focused solely upon their diagnostic accuracy. However,
this study has highlighted the importance of considering
clinical utility when assessing biomarkers. Interleukin-6
had the overall highest overall beneficial characteristics;
however, this neglects its 168-h process time and expensive
cost per test, which would preclude it from actual clinical
use. This is further highlighted by the sensitivity analysis,
which demonstrated that factoring in the significance of
costs, more traditional biomarkers such as WCC, will be
preferred. This study has therefore highlights the potential
importance of cost–benefit modeling to improve this
decision-making process when considering regional or
national allocation of resources for diagnostic
investigations.
In fact, no single biomarker had all the desired charac-
teristics for the diagnosis of acute appendicitis. More
commonly used biomarkers have less process-related costs
due to the widespread availability of the testing, but are of
relatively poor diagnostic accuracy when used in isolation.
New proposed biomarkers whilst having high diagnostic
value often require more complex assays, in which some
circumstances require them to be sent to regional centers
for analysis. However, a combination of biomarkers, as is
used by some institutions clinically with white cell count
and CRP, may improve the diagnostic ability [41, 45].
Alternatively, the use of a biomarker in conjunction with a
consistent clinical history and examination may improve
diagnostic accuracy in a more feasible manner. This could
be achieved by utilization of stratification scores such as
the Alvarado, which is a 10-point scoring system incor-
porating the typical signs and symptoms seen with
appendicitis. With a cutoff of 7, this diagnostic algorithm
has been shown to have a reported specificity as high as
100 % [75]. However, the limitation of the utilization of
these scoring systems is the subjective interpretation of
bFig. 3 A Cost–benefit trade-off for the six biomarkers. Benefits
include a summation sensitivity, specificity, predictive ability and
reproducibility. B Sensitivity analysis revealing the effect of changing
the current weighting (dashed line) placed upon financial cost and
overall benefits. C Sensitivity analysis revealing the effect of
changing the current weighting (dashed line) placed upon time for
result and overall benefits
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clinical history and examination findings [42]. Further-
more, a surgeon’s clinical impression has in some cases
been shown to be of equivalent diagnostic value as these
scoring systems, highlighting the value of clinical experi-
ence and the limitations of the widespread utilization of
scoring systems [36]. In effect, therefore we have shown
that clinically white cell count and bilirubin should be
considered of greater use in the diagnosis of acute appen-
dicitis when compared other biomarkers. However, given
the limitations associated with current biomarkers, a high
level of discrimination is required when interpreting these
in practice, and the use of clinical impression in conjunc-
tion with radiological investigations remains the mainstay
of the diagnostic paradigm.
The limitations of this study are primarily as a result of
the studies included to inform the cost–benefit trade-off.
Patient selection varied, and a lack of details regarding
exclusion criteria limited the applicability of the studies to
a patient population. Moreover, there was heterogeneity in
the study designs, with a number of retrospective studies
being included. Many of these trials did not explicitly
mention blinding of the investigators, which is another
potential source for bias and limitation of this review.
Inherently with the use of novel biomarkers, no preexisting
widely accepted threshold exists, leading many studies to
assess various diagnostic cutoff values. Without blinding
the investigators to the results of the histology, this
increases the scope for bias. Furthermore, these studies
often employed ‘healthy’ controls to formulate the testing
thresholds; however, minimal details were provided as to
the demographics of these controls, as well as leading to
the aforementioned issues regarding specificity. A further
limitation of this type of review is the potential for publi-
cation bias. Whilst this was mitigated by conducting a
thorough multi-database search, the presence of language
and publication bias still persists.
The results are further limited by the fact that the
weighting was based upon the results of an online survey
which had a response rate of 12.7 % and represented only
surgeons affiliated with the EAES. Moreover, as the best
overall marker changed with increasing the importance of
sensitivity, the reliance upon the weighting system
demonstrates how the conclusions would change depend-
ing on the opinions of the surgeons.
Conclusion
Appendicitis continues to pose a diagnostic challenge to
emergency physicians and surgeons. Clinical impression
remains a crucial tool in diagnosis, and treatment allocation
in those with suspected appendicitis. As yet no biomarker
has been shown to have sufficient diagnostic performance
to be used in isolation clinically. This would suggest that
further areas of research should focus upon the search for
new novel diagnostic tests and the clinical utility of the
tests, rather than repeat existing research into previously
studied biomarkers. Through this approach, the accuracy of
diagnosis of appendicitis can be enhanced, reducing the
number of negative appendectomies performed, implied
adverse impact to patients and treatment costs to hospitals.
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